NOM
NOM Finance, the private equity and venture capital branch of NV NOM Investerings- En Ontwikkelingsmaatschappij voor Noord-Nederland, focuses on fostering the growth of businesses in Northern Netherlands, particularly in the provinces of Groningen, Friesland, and Drenthe. The firm specializes in investments across various sectors including agro and food, information technology, life sciences, cleantech, healthcare, and high-tech industries, while intentionally avoiding primary agriculture, retail, and regional services. NOM Finance provides funding for seed and startup ventures, expansion, restructuring, and management buy-outs, typically investing between €0.5 million and €2.5 million in equity and mezzanine financing, as well as offering deferred loans ranging from €0.05 million to €1.5 million. The firm usually seeks minority stakes in its portfolio companies and aims for exits within five to seven years. Established in 1974 and headquartered in Groningen, NOM Finance plays a vital role in supporting entrepreneurs throughout the various stages of their businesses.
Flow is a FinTech startup focussed on money automation.Flow lets you automate transactions between your accounts. Based on triggers you can transfer your money automatically to the accounts you choose.
Detact Diagnostics B.V., founded in 2014 and based in Groningen, the Netherlands, specializes in the development and testing of bacterial detection solutions for healthcare institutions. The company offers b-Swab, an innovative real-time bacterial detection system that allows hospital staff to easily assess the presence of bacteria on various surfaces. This system is designed to be reliable, fast, and cost-effective, facilitating the monitoring of hygiene protocols to combat hospital-acquired infections (HAIs). By providing these solutions, Detact Diagnostics aims to enhance the safety of healthcare environments and mitigate health risks associated with bacterial contamination.
Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.
Mucosis B.V. is a clinical-stage biotechnology company based in the Netherlands, focused on developing innovative mucosal vaccines that can be administered needle-free through the nose or mouth. Its lead product candidate, SynGEM, is an intranasal vaccine aimed at preventing respiratory syncytial virus (RSV) infection. The company's vaccines utilize the patented Mimopath technology, which facilitates a more natural immune response and offers broad protection against infectious diseases. This approach has shown promise in both animal and human studies, particularly with the FluGEM vaccine candidate, by targeting the innate immune system through Toll-like receptor 2 (TLR2) to activate the adaptive immune response. Mucosis aims to address various infectious diseases, including RSV, pneumococci, and influenza.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.